Brain Neoplasms
126
17
21
62
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
17 trials with published results (13%)
Research Maturity
62 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.5%
17 terminated out of 126 trials
78.5%
-8.1% vs benchmark
6%
8 trials in Phase 3/4
27%
17 of 62 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 62 completed trials
Clinical Trials (126)
Al Prediction of Sarcopenia Risk in Neurocritical ICU Patients
Preoperative Embolization for Highly Vascular Brain Tumors
Susceptibility-Weighted Imaging in Preoperative Grading of Cerebral Gliomas
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Ciprofol, Propofol and Sevoflurane for Postoperative Delirium in Elderly Brain Tumor Patients
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
BRAINFUL (BRAIN Tumor Focused Ultrasound-enabled Liquid Biopsy) Trial
Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor Treatment
Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors
3D-ASL and TDD-MRI for True Progression and Pseudoprogression After Glioma Surgery
CONNEctome-guided Navigation for Eloquent-area Tumor Surgery Trial
Fast Brain MRI in Children With Suspected Brain Tumor
[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
MR Elastography in Intracranial Lesions: Feasibility & Accuracy
Use of Fluorescence in Gliomas
Guided Meditation During Radiation Therapy for Brain Tumors
OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients
Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison
Platelets Activation in Brain Neoplasms
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent